Nuvectis Pharma, Inc. (NASDAQ: NVCT), a biopharmaceutical company in Fort Lee, NJ, revealed that their new drug, ciprocopan (NXP100), an oral complement Factor B inhibitor, has been granted marketing approval by the National Medicinal Products Administration of China. This medication is intended for treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received treatment with complement inhibitors. Nuvectis specializes in developing therapies for complement-related conditions and oncology. This recent approval marks a significant milestone for the company's clinical-stage drug, providing a potentially effective treatment option for individuals with PNH.